Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II study of Prostvac-VF completes enrollment

July 12, 2005

Cell-based vaccine shows promise in prostate cancer

July 12, 2005

Human Genome Sciences monoclonal antibodies presented at recent congresses

July 12, 2005

Update on the antitumor efficacy of TG-4010 in NSCLC

July 11, 2005

First phase I/II data with HuMax-CD20 in follicular non-Hodgkin's lymphoma

July 11, 2005

Treatment intervals of 4-7 days necessary for HuCAL-derived antibody efficacy

July 11, 2005

Promising results reported for the CG-8123 anticancer vaccine in NSCLC

July 8, 2005

SGN-00101 studied for prevention of cervical cancer

July 8, 2005

Enhanced clinical benefits of galiximab plus rituximab in follicular non-Hodgkin's lymphoma

July 7, 2005

Second phase III study for GVAX vaccine for prostate cancer

July 7, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...